KTTA
Pasithea Therapeutics Corp
NASDAQ: KTTA · HEALTHCARE · BIOTECHNOLOGY
$0.69
+0.87% today
Updated 2026-04-30
Market cap
$17.21M
P/E ratio
—
P/S ratio
42.15x
EPS (TTM)
$-2.91
Dividend yield
—
52W range
$0 – $2
Volume
0.4M
Pasithea Therapeutics Corp (KTTA) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | $-38689.00 | $-3.17M | $-13.69M | $-13.43M | $-13.92M | $-15.21B |
| Capital expenditures | $1.00 | $21503.00 | $107102.00 | $34301.00 | $2.00 | $0.00 |
| Depreciation | $1379.00 | $1379.00 | $5094.00 | $648454.00 | $649029.00 | — |
| Stock-based comp | — | $471250.00 | $835064.00 | $592269.00 | $773693.00 | $297.47M |
| Free cash flow | $-38690.00 | $-3.20M | $-13.80M | $-13.46M | $-13.92M | $-15.21B |
| Investing cash flow | $-21503.00 | $-21503.00 | $-2.93M | $399006.00 | — | — |
| Financing cash flow | $282339.00 | $55.93M | $-3.21M | $-3.73M | $4.52M | — |
| Dividends paid | — | — | — | — | $359.66M | — |
| Share repurchases | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — |
| Net change in cash | — | — | — | — | — | — |